JLK Signs Medical AI Solution Sales Collaboration Agreement with Japan's CMI

JLK (CEO Dongmin Kim) , a medical artificial intelligence (AI) company, announced on the 29th that it has signed a sales cooperation agreement with Century Medical Inc. (CMI), a Japanese medical device trading company. This agreement was concluded between JLK Japan, JLK's local Japanese subsidiary, and CMI.

CMI, a subsidiary of the Itochu Group, one of Japan's five largest general trading companies, has brought innovative medical devices from overseas to Japan, leveraging nearly 50 years of experience. Its strength lies in the sales of medical devices for ischemic stroke and cerebral aneurysm treatment, and synergy with JLK's AI stroke solution is expected.

This agreement will see CMI serve as a sales partner for JLK's AI solutions in the Japanese market. This will enable JLK to expand its key sales channels in Japan and accelerate its market entry.

JLK has already obtained seven approvals from the Pharmaceuticals and Medical Devices Agency (PMDA) and has secured the trust of Japanese medical professionals through numerous papers and research achievements. Since medical AI solutions typically require doctors to verify product efficacy based on research results and papers, JLK has leveraged prior research and clinical data to establish a foundation for product adoption.

JLK has been pursuing a phased strategy for entering the Japanese market, including this agreement, including obtaining medical device approvals and collaborating with hospital clinical trials. Notably, CMI already handles stroke-related medical devices, and it is expected to leverage its existing sales network to rapidly expand the market.

JLK CEO Kim Dong-min stated, "This contract with CMI is the first step toward translating the technological trust we've built into tangible sales. CMI's sales network and our technological prowess will combine to drive rapid results in the Japanese market." He added, "We anticipate that our research findings and academic papers will translate into sales and profits, and this agreement will be the starting point for our full-fledged growth in the Japanese market."

• See more related articles